Ameritas Investment Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Ameritas Investment Partners’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,561	Closed	-$29K	–	3224
2020 Q1	$29K	Hold	7,561	–	–	﹤0.01%	1979
2019 Q4	$38K	Buy	7,561 +1,390	+23%	+$7.35K	﹤0.01%	2075
2019 Q3	$31K	Buy	6,171 +300	+5%	+$1.5K	﹤0.01%	2159
2019 Q2	$36K	Hold	5,871	–	–	﹤0.01%	2112
2019 Q1	$27K	Hold	5,871	–	–	﹤0.01%	2236
2018 Q4	$25K	Hold	5,871	–	–	﹤0.01%	2222
2018 Q3	$37K	Hold	5,871	–	–	﹤0.01%	2166
2018 Q2	$47K	Hold	5,871	–	–	﹤0.01%	2028
2018 Q1	$44K	Hold	5,871	–	–	﹤0.01%	1988
2017 Q4	$35K	Hold	5,871	–	–	﹤0.01%	2130
2017 Q3	$39K	Hold	5,871	–	–	﹤0.01%	2044
2017 Q2	$40K	Hold	5,871	–	–	﹤0.01%	2061
2017 Q1	$55K	Buy	+5,871	New	+$58.6K	﹤0.01%	1785

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Ameritas Investment Partners's PGNX Position: Q2 2020 in Review

Ameritas Investment Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 7,561 shares — an estimated $29K sold.

Ameritas Investment Partners first reported a position in PGNX in Q1 2017 and held it in 13 quarters. The position peaked at $55K in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Ameritas Investment Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Ameritas Investment Partners sold 7,561 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $29K.
Ameritas Investment Partners first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 13 quarters.
Ameritas Investment Partners's Progenics Pharmaceuticals Inc position peaked at $55K in Q1 2017.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Ameritas Investment Partners's 13F filing for Q2 2020, filed 5 Aug 2020.